Technology implementation of nucleic acids for viral safety of blood products in Cuba

Abstract

Implementing NAT in blood serum Products Enterprise “Adalberto Pesant” for viral screening of blood plasma dedicated to manufacturing. The firm was hired and cobas s 201 system was implemented for screening in plasma to Human Immunodeficiency Viruses (HIV), Hepatitis C (HCV) and Hepatitis B (HBV). A descriptive, longitudinal study and with qualitative paradigm was carried out in the period from January 2011 to July 2015. With a total 1 273 014 screening plasma units, 122 samples were PCR-reactive (0.01 %). The distribution was 80/122 (65.57 %) reactive to HBV, 35/122 (28.69 %) reactive to HVC and 7/122 (5.74 %) reactive to HIV. PCR results as well as the serological tests and additional enzyme immunoassays carried out in LISIDA, facilitated the feedback with the involved blood banks and another centers, being notified 67 samples (54.92 %) UMELISA reactive and 55 samples (45.08 %) in window period, that allows the study of supposedly healthy blood donors with viral infections that facilitates the opportune treatment of these donors. The technological, economic and social benefits of NAT implementation were demonstrated, it evidenced the necessity of analytical techniques development that reinforce the viral security of sanguine components for chemotherapy, the raw materials given to the industry and obtained products.